Toggle navigation
Toggle navigation
Home
DCUM Forums
Nanny Forums
Events
About DCUM
Advertising
Search
Recent Topics
Hottest Topics
FAQs and Guidelines
Privacy Policy
Your current identity is: Anonymous
Login
Preview
Subject:
Forum Index
»
Tweens and Teens
Reply to "Teen balding"
Subject:
Emoticons
More smilies
Text Color:
Default
Dark Red
Red
Orange
Brown
Yellow
Green
Olive
Cyan
Blue
Dark Blue
Violet
White
Black
Font:
Very Small
Small
Normal
Big
Giant
Close Marks
[quote=Anonymous]It all comes down to inflammation and the JAK-Stat pathway can help to mitigate that - but glucose spikes cause it. You can take a topical JAK inhibitor but they aren't currently widely available. https://www.healio.com/news/dermatology/20190619/jak-inhibitor-promotes-hair-growth-in-both-men-women-with-androgenetic-alopecia ATI-502 (Aclaris), an investigational topical Janus kinase (JAK) 1/3 inhibitor, was evaluated in adult women and men with androgenetic alopecia (AGA) and applied to the scalp twice daily for 26 weeks. Twenty-three of 31 subjects completed 6 months of treatment. Twenty subjects, 14 men and 6 women, had evaluable hair counts, and 22 subjects recorded investigator global assessment and subject self-assessment scores. The mean change from baseline in non-vellus target area hair count (TAHC) at week 26 was the primary endpoint. The TAHC increase was 15.3 hairs/cm2 in female subjects and 5.6 hairs/cm2 in males, according to a press release from Aclaris. The investigators rated 16 of 22 subjects (73%) as experiencing increased hair growth, and 18 of 22 subjects (82%) rated themselves as experiencing increased hair growth. “By inhibiting the local inflammation, you remove that [resting phase and hair loss effect], allowing hair follicle stem cell activation, pushing that follicle back into the anagen phase,” Walker said. The effect in female subjects was particularly strong, according to Walker. A continued linear hair increase was seen up to 6 months, which is not typical in this condition, he said. Twelve-month results from this trial are expected by the end of the year. The treatment is nonhormonal, Walker said, and could be used in a variety of options, such as in monotherapy or in combination with existing therapies. “One thing that surprised me was how robust the female data was,” Walker said. “ Most people who work in hair loss studies look at males first, then go to females. We just decided to do both. I think that was a pleasant surprise.”[/quote]
Options
Disable HTML in this message
Disable BB Code in this message
Disable smilies in this message
Review message
Search
Recent Topics
Hottest Topics